Abstract
‚A decision that supports and strengthens Germany as a business location‘ (Habeck); ‚A really good day for Germany‘ (Lauterbach). It is rare for two federal ministers - Prof Dr Karl Lauterbach (Health) and Dr Robert Habeck (Economics and Vice-Chancellor) - to appear together at a press conference organised by a pharmaceutical company. All that was missing was Bettina Stark-Watzinger, Federal Minister of Education and Research, to round off the triumvirate of ministries significantly involved in the topic. After all, the research-based pharmaceutical company Eli Lilly and Company announced far-reaching investment plans in Germany in Berlin: from 2024, the construction of a new high-tech production facility in Alzey - subject to the approval of the state authorities - is to begin at a cost of 2.3 billion euros. Around 1,900 employees will initially work in the new production network, rising to around 1,000 after completion in 2027.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
